Inhibin immunoreactivity in gonadal and non-gonadal tumors by Jong, F.H. (Frank) de et al.
J. Steroid Biochem. Molec. Biol. Vol. 37, No. 6, pp. 863-866, 1990 0960-0760/90 $3.00 + 0.00 
Printed in Great Britain. All rights reserved Copyright © 1990 Pergamon Press plc 
INHIBIN IMMUNOREACTIVITY IN GONADAL AND 
NON-GONADAL TUMORS 
F. H. DE JONG, 12 A. J. GROOTENHUIS, ] J. STEENBERGEN, 1F. J. VAN SLUIJS, 4 J. A. FOEKENS, 5 
F. J. W. TEN KATE, 3 J. W. OOSTERHUIS, 6S. W. J. LAMBERTS 2 and J. G. M. KLIJN 5 
Departments of ~Biochemistry (Division of Chemical Endocrinology), 2Internal Medicine and SPathology, 
Erasmus University Rotterdam, 4Department of Clinical Sciences of Companion Animals, State Univer- 
sity Utrecht, 5Division of Endocrine Oncology, Dr Daniel den Hoed Cancer Center, Rotterdam and 
6Department of Pathology, State University Groningen, The Netherlands 
Summary--Inhibin immunoreactivity was estimated in a number of gonadal and non-gonadal 
tumors. Dog Sertoli cell tumors and human granulosa cell and Leydig cell tumors contained 
high concentrations of inhibin-like material. Levels, comparable with those in normal testes 
and ovaries were detected in human testicular non-seminomas nd in ovarian cystadenomas, 
thecomas and adenofibromas. No activity was found in human testicular Sertoli/Leydig cell 
tumors and seminomas and in ovarian adenocarcinomas, teratomas and a dysgerminoma. 
Furthermore, human adrenal cortical tissue (tumor and hyperplastic adrenal) contained 
inhibin immunoreactivity. No activity was found in human tumors of the stomach, gut, liver, 
kidney, pancreas and mammary gland or in meningiomas. It is concluded that inhibin is not 
a good marker for specific gonadal tumors. Inhibin might have intratumor actions as a growth 
or differentiation factor. 
INTRODUCTION 
lnhibin has been defined as a gonadal glyco- 
protein hormone, which can suppress the 
pituitary production and secretion of gonado- 
tropins, preferentially that of FSH [1]. Inhibin 
consists of two disulphide-linked subunits: the 
-subunit is combined with either of two/?-sub- 
units, fl-A or fl-B. The primary structure of the 
inhibin subunits hows homology with that of a 
number of growth and differentiation factors, 
e.g. Miillerian inhibiting substance and trans- 
forming growth factor-/? (see for reviews, De 
Jong[2], Ying[3], de Kretser and Robert- 
son [4]). Combination of two inhibin fl-subunits 
leads to the formation of activin, a protein 
which counteracts the action of inhibin on the 
pituitary secretion of FSH [5, 6]. 
The mRNA for the inhibin subunits is ex- 
pressed in a large number of tissues apart from 
the gonads [7], and even in the gonads them- 
selves inhibin subunits have been detected out- 
side the cells which were traditionally believed 
to be the source of inhibin viz. the Sertoli cells 
in the testis [8] and the granulosa cells in the 
ovary [9]: Lee et al. [10] and Risbridger et al. [11] 
showed inhibin production in Leydig cells, 
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whereas a number of other authors showed the 
presence of inhibin subunits in theca or corpus 
luteum cells in the ovary (see for review, de Jong 
et al. [12]). 
Recently, the presence of high peripheral 
levels of inhibin immunoreactivity in women 
with granulosa cell tumors was described [13]. 
In the present study, levels of inhibin im- 
munoreactivity in human ovarian and testicular 
tumor tissue were estimated in order to ascer- 
tain the specificity of inhibin as a marker for 
granulosa and Sertoli cell tumors. Because of 
the fact that the incidence of Sertoli cell tumors 
in men is extremely low, this type of tumor was 
obtained from dogs. Finally, in order to sub- 
stantiate the specificity of inhibin as a gonadal 
tumor marker, inhibin immunoreactivity was 
also estimated in a number of tumors of other 
organs. 
MATERIALS AND METHODS 
Tumor  tissues 
Sertoli cell tumors were obtained from dogs, 
whereas all other tumor material was of human 
origin. All tumor tissues were placed on ice 
immediately after excision. Part of the tissue 
was used for routine pathological procedures; 
the remaining tissue was stored at -80°C until 
processing. The frozen tissue was pulverized 
and homogenized as described earlier [14]. The 
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homogenates were centrifuged for 30 min at 
50,000g at 4°C, and the supernatant was used 
for the estimation of inhibin (see below) and 
protein [15]. 
Inhibin assays 
Inhibin immunoreactivity was assayed using 
the antiserum against bovine inhibin (No. 1989) 
described by Robertson et al. [16], using radio- 
iodinated 32 kDa bovine inhibin as a label. The 
antiserum and the material for iodination were 
purchased from the Department of Anatomy, 
Monash University, Melbourne, Australia. In- 
hibin was labeled using [~25I]sodium iodide 
(Amersham, Amersham, U.K.) and Protag 
(Baker, Deventer, The Netherlands) as the oxi- 
dizing agent. Labeled protein was isolated after 
chromatography on prepacked Sephadex G-25 
columns (PD- 10, Pharmacia, Uppsala, Sweden). 
The standard used in the immunoassay was a 
bovine ovarian follicular fluid preparation with 
the arbitrary potency of 1 U/#g protein. The 
International Research Standard for inhibin 
(86/890, [17]), has a specific activity of 
60 4-10U/#g, when expressed in units of this 
bovine follicular fluid standard. 
Inhibin bioactivity was estimated as described 




Dog Sertoli cell tumors. Inhibin bioactivity 
levels in the Sertoli cell tumors and in canine 
control testes are shown in Fig. 1, together 
with the results of the immunological esti- 
mations of inhibin in plasma from these ani- 
mals. Testicular inhibin bioactivity in the tumor 
tissue was significantly higher than that in the 
control testes (P < 0.05). Similarly, the periph- 
eral levels of immunoreactive inhibin were sig- 
nificantly higher when compared with those 
in control dogs (P <0.01 after logarithmic 
transformation). There was no relationship be- 
tween testicular and peripheral concentrations 
of inhibin. 
Human testis tumors. Results of estimations 
of immunoreactive inhibin in homogenates of
human testicular tumors are summarized in 
Fig. 2. High concentrations were found in two 
out of three Leydig cell tumors, whereas non- 
seminomas contained inhibin levels comparable 
to those in normal human testes. In contrast, 
very low concentrations or non-detectable levels 
were found in mixed Sertoli cell-Leydig cell 
tumors and in seminomas. 
Ovarian tumors 
Levels of immunoreactive inhibin in human 
ovarian tumors are shown in Fig. 3. Significant 
concentrations were found in control ovaries, 
cystadenomas, thecomas and adenofibromas, 
whereas much higher levels were present in the 
supernatant of the granulosa cell tumor hom- 
ogenates. The concentrations of inhibin im- 
munoreactivity in adenocarcinomas, teratomas 
and a dysgerminoma were below the level of 
detection of the assay. 
Other tumors 
Finally, inhibin immunoreactivity was esti- 
mated in supernatants of homogenates of a 
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Fig. 1. Bioactive inhibin in control testes (open bar) or Sertoli cell tumors (hatched bar) from dogs and 
immunoreactive inhibin in plasma from the same animals (means -4- SEM, n = 5). Data from Grootenhuis 
et al. [20]. 
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Fig. 2. Inhibin levels in human control testes and in testicular neoplasms: Leydig cell tumors (LC), 
nonseminomas (Nonsem), Sertoli cell/Leydig cell tumors (SC/LC) and seminomas (Sem). Figures indicate 
numbers of samples investigated. 
number of other tumors. Inhibin was only de- 
tected in adrenal cortical tissue (hyperplastic 
adrenal: 3 U/mg protein; adrenal tumor: 
1 U/mg protein), whereas no immunoreactivity 
was found in tumors of the stomach (n = 3), gut 
(n = 4), liver (n = 3), kidney (n = 3), pancreas 
(n=2)  and mammary gland (n=5)  or in 
meningiomas (n = 5). 
DISCUSSION 
Bioactive inhibin is produced in the granulosa 
cells of the ovary [9] and the Sertoli cells of the 
testis[8]. Furthermore, inhibin bio- and im- 
munoactivity has been reported to be present in 
culture medium of Leydig cells [10, 11] and the 
presence of inhibin subunits has been reported in 
a number of other tissues including the adrenal 
gland, the kidney and the brain (see [12]). 
The results reported here indicate the pres- 
ence of inhibin immunoreactivity n Sertoli and 
granulosa cell tumors. It is not clear if this 
immunoreactivity should be ascribed to dimers 
of the inhibin ~- and fl-subunits or to the 
presence of an ~-subunit, combined with part of 
its pro-sequence, which was shown to cross- 
react in the immunoassay used here [19]. Also, 
high circulating levels of immunoreactive in- 
hibin were found in dogs with Sertoli cell 
tumors [20] and in women with granulosa cell 
tumors [13]. However, other types of tumors in 
the testis and the ovary also appear to contain 
inhibin immunoreactive material; in patients 
with these types of tumor increased peripheral 
levels of inhibin might also occur, thus render- 
ing the specificity of inhibin as a marker for 
granulosa nd Sertoli cell tumors questionable. 
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Fig. 3. Inhibin levels in human control ovaries and in ovarian neoplasms: granulosa cell tumors (GC), 
cystadenomas (Cyst), thecomas (Thec), adenofibromas (Adfibr), adenocarcinomas (AdCa), teratomas 
(Ter) and a dysgerminoma (Dysg). Figures indicate numbers of samples investigated. 
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not contain detectable amounts of inhibin 
immunoreactivity. 
The presence of inhibin immunoreactivity in 
testicular non-seminomas is interesting, since 
this tumor may consist of a number of primitive 
cell types; so far, no clear correlation with a 
subtype of non-seminomas was observed. The 
finding that mixed Leydig-Sertoli cell tumors 
did not contain inhibin immunoreactivity is not 
understood, since both cell types contributing to 
this tumor apparently contain high concen- 
trations of the immunoreactivity. Finally, the 
presence of high concentrations of inhibin-like 
material in tumor tissues and the large number 
of intra- and extra-gonadal effects of inhibin 
and related substances (see [12]), suggest that 
inhibin may affect cellular functions in the 
tumor, or in other cell types, such as erythro- 
poietic cells [21] or thymocytes [22]. These poss- 
ible effects of inhibin and related proteins as 
growth and differentiation factors should be 
envisaged when dealing with patients with 
inhibin-producing tumors. 
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